-2.13%
-1.59%
-14.25%
-14.31%
20.77%
-5.74%
19.03%
AI Spotlight on KYMR
Company Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Market Data
| Last Price | 39.59 |
| Change Percentage | -2.13% |
| Open | 40.72 |
| Previous Close | 40.45 |
| Market Cap ( Millions) | 2564 |
| Volume | 392629 |
| Year High | 53.27 |
| Year Low | 29.24 |
| M A 50 | 42.62 |
| M A 200 | 41.53 |
Financial Ratios
| FCF Yield | -5.78% |
| Dividend Yield | 0.00% |
| ROE | -24.96% |
| Debt / Equity | 9.88% |
| Net Debt / EBIDTA | 13.97% |
| Price To Book | 3.38 |
| Price Earnings Ratio | -18.0 |
| Price To FCF | -17.3 |
| Price To sales | 29.28 |
| EV / EBITDA | -15.79 |
News
- Jan -30 - Kymera Therapeutics to Participate in Upcoming February Investor Conferences
- Jan -15 - Kymera Provides Pipeline Objectives for 2025, Stock Gains
- Jan -14 - Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
- Jan -07 - Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14
- Dec -07 - Kymera: Protein Degradation Could Drive Dupixent-Like Value
- Nov -26 - Kymera Therapeutics to Participate in Upcoming December Investor Conferences
- Nov -05 - Kymera Therapeutics to Participate in Upcoming November Investor Conferences
- Nov -03 - Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript
- Nov -01 - Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
- Oct -31 - Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates
- Oct -31 - Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
- Oct -24 - Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases
- Oct -23 - Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
- Oct -10 - Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
- Oct -09 - Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
- Oct -06 - Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
- Sep -25 - Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
- Sep -06 - Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?
- Aug -28 - Kymera Therapeutics to Participate in Upcoming September Investor Conferences
- Aug -21 - Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Small Molecule Therapeutics
Expected Growth : 9.27 %
What the company do ?
Small Molecule Therapeutics from Kymera Therapeutics, Inc. is a novel E3 ubiquitin ligase-based protein degradation platform for targeted protein degradation.
Why we expect these perspectives ?
Kymera Therapeutics' Small Molecule Therapeutics segment growth of 9.27% is driven by increasing demand for targeted protein degradation therapies, strategic partnerships, and a strong pipeline of novel E3 ubiquitin ligase-based molecules. Additionally, advancements in PROTAC technology and expanding research in oncology and immunology further fuel growth.
Kymera Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| KT-474 | A novel, orally bioavailable, irreversible inhibitor of the ubiquitin ligase cereblon, for the treatment of multiple myeloma and other hematologic malignancies. |
| KT-333 | A novel, orally bioavailable, irreversible inhibitor of the ubiquitin ligase IRAK4, for the treatment of immune-inflammatory diseases. |
| E3 ubiquitin ligase degraders | A novel class of targeted protein degraders that harness the body's natural protein degradation machinery to eliminate disease-causing proteins. |
Kymera Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
Kymera Therapeutics, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
Bargaining Power Of Customers
Kymera Therapeutics, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are highly specialized, making it difficult for customers to switch to alternative suppliers.
Bargaining Power Of Suppliers
Kymera Therapeutics, Inc. relies on a few key suppliers for raw materials and services, which gives them some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate contracts mitigate this risk.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant capital requirements, complex regulatory requirements, and the need for specialized expertise. This makes it difficult for new entrants to enter the market.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. Kymera Therapeutics, Inc. faces intense competition from companies with similar products and technologies.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 17.65% |
| Debt Cost | 3.95% |
| Equity Weight | 82.35% |
| Equity Cost | 15.51% |
| WACC | 13.47% |
| Leverage | 21.44% |
Kymera Therapeutics, Inc. : Quality Control
Kymera Therapeutics, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OABI | OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies … |
| SYRS | Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates … |
| DNTH | Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that … |
| MNKD | MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled … |
| TCRX | TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
MannKind
A-Score
1-Year Total Return ->
🥈
Dianthus Therapeutics
A-Score
1-Year Total Return ->
🥉
Kymera Therapeutics
A-Score
1-Year Total Return ->
4
OmniAb
A-Score
1-Year Total Return ->
5
Syros Pharmaceuticals
A-Score
1-Year Total Return ->
6
